Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung cancers; yet the durability of response is limited by drug resistance. Elucidation of on-target resistance mechanisms...
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNAALKLiquid biopsyNon-small cell lung cancerTherapy monitoringBackground Targeted therapies (TKI) have improved the prognosis of ALK-rearranged lung cancer (ALK NSCLC), but...
ALK依赖性耐药 在约50-60%对第二代ALK-TKI耐药的患者中,ALK基因激酶结构域出现的继发突变(Secondary Mutation)是导致耐药的原因,涉及的机制包括直接阻碍ALK-TKI与位点结合,导致蛋白激酶构象改变和/或影响ATP结合等。 与第一代/第二...
5.Shiba-Ishii A, Johnson TW, Dagogo-Jack I, et al. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nat Cancer. 2022. 3(6): 710-722. ...
[1]Solomon B J, Bauer T M, Mok T S K, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study[J]. The Lancet Respiratory ...
ALK-positive lung cancer: a moving target[J]. Nature Cancer, 2023.[3]Shiba-Ishii A, Johnson T W, Dagogo-Jack I, et al. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer[J]. Nature Cancer, 2022, 3(6): 710...
[4]Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.[5]Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung cancer.[6]First-line ceritinib versus platinum-based chemotherapy in ...
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J]. N Engl J Med. 2013;368(25):2385-2394. [4] Solomon BJ, Kim DW, Wu YL, et al. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell ...
[3]Solomon BJ, Kim DW, Wu YL, et al. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 Aug 1;36(22):2251-2258. doi: 10.1200/JCO.2017.77.4794. ...
[5] Shaw A T, Bauer T M, Marinis F D, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer[J]. New England Journal of Medicine, 2020, 383(21):2018-2029. [6] Yang Y, Zhou J, Zhou J, et al. Efficacy, safety, and biomarker analysis of ensartini...